Literature DB >> 35272743

Th1/Th17-mediated Immunity and Protection from Peripheral Neuropathy in Wildtype and IL10-/- BALB/c Mice Infected with a Guillain-Barré Syndrome-associated Campylobacter jejuni Strain.

Jean M Brudvig1, Matthew M Cluett2, Elizabeth U Gensterblum-Miller3, James Chen3, Julia A Bell3, Linda S Mansfield4.   

Abstract

Campylobacter jejuni is an important cause of bacterial gastroenteritis worldwide and is linked to Guillain-Barré syndrome (GBS), a debilitating postinfectious polyneuropathy. The immunopathogenesis of GBS involves the generation of antibodies that are cross reactive to C. jejuni lipooligosaccharide and structurally similar peripheral nerve gangliosides. Both the C. jejuni infecting strain and host factors contribute to GBS development. GBS pathogenesis is associated with Th2-mediated responses in patients. Moreover, induction of IgG1 antiganglioside antibodies in association with colonic Th2-mediated immune responses has been reported in C. jejuni-infected C57BL/6 IL10-/- mice at 4 to 6 wk after infection. We hypothesized that, due to their Th2 immunologic bias, BALB/c mice would develop autoantibodies and signs of peripheral neuropathy after infection with a GBS patient-derived strain of C. jejuni (strain 260.94). WT and IL10-/- BALB/c mice were orally inoculated with C. jejuni 260.94, phenotyped weekly for neurologic deficits, and euthanized after 5 wk. Immune responses were assessed as C. jejuni-specific and antiganglioside antibodies in plasma and cytokine production and histologic lesions in the proximal colon. Peripheral nerve lesions were assessed in dorsal root ganglia and their afferent nerve fibers by scoring immunohistochemically labeled macrophages through morphometry. C. jejuni 260.94 stably colonized both WT and IL10-/- mice and induced systemic Th1/Th17-mediated immune responses with significant increases in C. jejuni-specific IgG2a, IgG2b, and IgG3 plasma antibodies. However, C. jejuni 260.94 did not induce IgG1 antiganglioside antibodies, colitis, or neurologic deficits or peripheral nerve lesions in WT or IL10-/- mice. Both WT and IL10-/- BALB/c mice showed relative protection from development of Th2-mediated immunity and antiganglioside antibodies as compared with C57BL/6 IL10-/- mice. Therefore, BALB/c mice infected with C. jejuni 260.94 are not an effective disease model but provide the opportunity to study the role of immune mechanisms and host genetic background in the susceptibility to post infectious GBS.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35272743      PMCID: PMC9084571          DOI: 10.30802/AALAS-CM-21-000059

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   1.565


  63 in total

1.  Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

Authors:  R D Hadden; H Karch; H P Hartung; J Zielasek; B Weissbrich; J Schubert; A Weishaupt; D R Cornblath; A V Swan; R A Hughes; K V Toyka
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Differences in interleukin-12 and -15 production by dendritic cells at the early stage of Listeria monocytogenes infection between BALB/c and C57 BL/6 mice.

Authors:  T Liu; H Nishimura; T Matsuguchi; Y Yoshikai
Journal:  Cell Immunol       Date:  2000-05-25       Impact factor: 4.868

3.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

4.  Response to ethanol induced ataxia between C57BL/6J and 129X1/SvJ mouse strains using a treadmill based assay.

Authors:  Stephen T Hansen; Stefan M Pulst
Journal:  Pharmacol Biochem Behav       Date:  2012-10-24       Impact factor: 3.533

5.  A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome.

Authors:  R Louwen; D Horst-Kreft; A G de Boer; L van der Graaf; G de Knegt; M Hamersma; A P Heikema; A R Timms; B C Jacobs; J A Wagenaar; H P Endtz; J van der Oost; J M Wells; E E S Nieuwenhuis; A H M van Vliet; P T J Willemsen; P van Baarlen; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-04       Impact factor: 3.267

6.  Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

Authors:  Susan K Halstead; Femke M P Zitman; Peter D Humphreys; Kay Greenshields; Jan J Verschuuren; Bart C Jacobs; Russell P Rother; Jaap J Plomp; Hugh J Willison
Journal:  Brain       Date:  2008-01-08       Impact factor: 13.501

7.  The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

Authors:  R M Martin; J L Brady; A M Lew
Journal:  J Immunol Methods       Date:  1998-03-15       Impact factor: 2.303

Review 8.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

9.  Bacterial AB5 toxins inhibit the growth of gut bacteria by targeting ganglioside-like glycoconjugates.

Authors:  Robert T Patry; Martin Stahl; Maria Elisa Perez-Munoz; Harald Nothaft; Cory Q Wenzel; Jessica C Sacher; Colin Coros; Jens Walter; Bruce A Vallance; Christine M Szymanski
Journal:  Nat Commun       Date:  2019-03-27       Impact factor: 14.919

10.  A comparison of DigiGait™ and TreadScan™ imaging systems: assessment of pain using gait analysis in murine monoarthritis.

Authors:  Christopher W Dorman; Hollis E Krug; Sandra P Frizelle; Sonia Funkenbusch; Maren L Mahowald
Journal:  J Pain Res       Date:  2013-12-24       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.